Cargando…
Current strategies for targeting the activity of androgen receptor variants
Current therapies for advanced prostate cancer, such as enzalutamide and abiraterone, focus on inhibiting androgen receptor (AR) activity and reducing downstream signaling pathways to inhibit tumor growth. Unfortunately, cancer cells are very adaptable and, over time, these cells develop mechanisms...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Second Military Medical University
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363599/ https://www.ncbi.nlm.nih.gov/pubmed/30775247 http://dx.doi.org/10.1016/j.ajur.2018.07.003 |